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R E S E A R C H  L E T T E R
Improved anaphylaxis referral rates to specialized services from 
an Emergency Department
To the Editor,
The UK has high allergy prevalence rates, with 30%-40% of the 
population affected by allergy. Hospital admissions for anaphylaxis, 
its most severe manifestation, have increased sevenfold since 1990.1 
It has long been thought by many that most patients attending hos-
pital as an emergency with anaphylaxis are not referred for special-
ist evaluation to determine its cause.2 This is important in order to 
identify causative allergens that should be avoided and formulate a 
plan for managing reactions including training in adrenaline self-ad-
ministration.3,4 Evaluating such patients is a function of a specialized 
allergy service as delineated in the UK by the Department of Health 
Specialised Services Definition set No 17.
Cardiff and Vale University Health Board hosts the only 
Specialised Adult Allergy Service (SAAS) for adults in Wales. We per-
formed an audit in 2007 to determine how many patients attending 
the Health Board's Accident and Emergency Department (A&E) with 
anaphylaxis were referred and subsequently seen in the SAAS. We 
found that 77 patients attended A&E with anaphylaxis in a 6-month 
period in 2007 but none of these were referred to the SAAS.5 In 
December 2011, the National Institute for Clinical Excellence (NICE) 
published guidelines advising that after emergency treatment for 
suspected anaphylaxis all patients should be offered referral to 
a SAAS and an appropriate adrenaline injector as an interim mea-
sure before the specialist appointment.6 In 2012 and 2013, both 
Departments implemented a streamlined referral pathway for these 
patients and we now report on the effect of these changes.
On arrival at A&E, patients are triaged and treated appropriately 
and a decision made whether to admit or discharge patients who 
have had anaphylaxis. In response to the NICE guidelines, the A&E 
Department introduced in 2013 a comprehensive pro forma docu-
ment for completion by A&E staff that detailed clinical aspects of 
patients’ presentation with anaphylaxis and its urgent management 
that incorporated a referral form to the Department of Immunology 
and Allergy for direct patient referral to the SAAS if indicated.
The Department of Immunology and Allergy wrote a 3-page doc-
ument (Supplementary information) that defined anaphylaxis, listed 
its major causes and indicated what long-term changes to patients' 
treatments should be made immediately, which patients should be 
referred to the SAAS and which should be followed up in primary 
care. It was written to distinguish isolated urticaria and angioedema 
clearly from anaphylaxis (in order to solicit referral only of patients 
who had had anaphylaxis) and concisely listed major causes of these 
conditions and their appropriate management. A request was made 
for this to be given to the patient to give to their GP (in the case 
of patients who did not require hospital admission or specialist fol-
low-up, for example when a drug might be stopped or changed if 
causing drug-induced anaphylaxis) to help inform onward primary 
care management.
We also established in January 2012 a monthly rapid access out-
patient allergy clinic so that all patients referred from A&E with ana-
phylaxis could be seen within 6 weeks.
The medical records of all patients attending A&E are encoded 
in an electronic database. In the initial audit, patients attending 
A&E with anaphylaxis during the 6-month period 1 April to 30 
September 2007 were identified by searching the electronic data-
base using the likely keywords: allergic, allergy, anaphylaxis, anaphy-
lactic, rash, swelling, breathing difficulties, vasovagal episode/attack, 
convulsion, bite, sting, local infection, insect, bruise, abdominal pain, 
asthma, reaction or pyrexia. These identified 200 patients whose 
full A&E records were retrieved for further scrutiny, among whom 
77 patients with anaphylaxis requiring specialist assessment were 
identified. In the re-audit of patients attending during the same 
6-month period from 1 April 2016 to 30 September 2016, the 
(same) keywords were used, and the keywords nut and food were 
added in order to increase the likelihood of identifying patients. 
Each full A&E record of patients identified was scrutinized care-
fully to ascertain exactly which patients should have been referred 
to the SAAS. The work was approved by the Health Board's Clinical 
Audit Department.
The SAAS database was searched to ensure that all patients re-
ferred to the allergy service during the period of the audit would 
have been identified, even if they had been wrongly given a routine 
rather than a rapid access clinic appointment.
In the 2007 audit, 3500 A&E patient records were identified from 
the keyword search and 77 cases of anaphylaxis identified, none of 
whom were referred to the SAAS. In the 2016 re-audit, 6590 records 
were identified and only 41 patients were identified as having had 
anaphylaxis indicating that they should have been referred to the 
SAAS. Only 18 of these 41 patients were actually referred. All were 
given urgent appointments, and 17 attended (Figure 1).
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The 18 patients referred (R) and the 23 patients not referred (NR) 
were similar in the A&E assessment of the number that had had reac-
tions to food (12R, 10NR), medications (4R, 3NR), insects (0R, 1NR) 
or plants (0R, 1NR). Suspected precipitants in 10 patients (2R, 8NR) 
were not documented. Epinephrine for self-administration devices 
were required for 17 of the 41 patients who required referral and 
were prescribed by A&E to 14 of those patients (82%), not having 
been recorded as being prescribed to 3 patients with food allergy 
(2 to nuts, 1 to egg). Epinephrine was not prescribed to 16 patients 
(9R, 7NR) at discharge from A&E whose symptoms were due to side 
effects of NSAIDs, salicylates, other drugs or oral allergy syndrome 
or who had mild wheezing only, in whom drug therapy was appropri-
ately changed and avoidance of the identified precipitant advised. In 
the remaining 8 patients not referred to the SAAS, the A&E records 
were not sufficiently detailed to ascertain if epinephrine device pre-
scription was indicated.
More A&E attendees were identified in 2016 (6590) than in 
2007 (3500) indicating the increase in number of patients without 
anaphylaxis attending A&E. The changes were made in the doc-
umentation and patient referral pathway was associated with an 
improvement in the rate of referral of patients to the SAAS from 
0/77 = 0% in 2007 to 18/41 = 44% in 2016. This is a significant 
improvement in performance, although there is room for further 
improvement.
World Allergy Organisation anaphylaxis guidelines in 2011 rec-
ommended that at the time of discharge from a healthcare setting 
such patients should be equipped with epinephrine for self-admin-
istration and taught why, when and how to administer it, given a 
written personalized anaphylaxis emergency action plan stating the 
common symptoms and signs of anaphylaxis, and medical identifi-
cation.7 We wrote our document to guide the onward management 
of these patients by referral to the SAAS or to their GP to facilitate 
immediate changes in drug treatment if required, and to aid the man-
agement of patients with spontaneous urticaria or angioedema who 
might be more appropriately managed in primary care.
The incidence of anaphylaxis has been reported in 2008 to 
vary from 3.2 to 20 per 100 000 8 or to 49.8 per 100 000 when 
reliance was not placed upon hospital coding systems.9 Despite 
the reported rising incidence of anaphylaxis,1 we found a lower 
incidence in 2016 (41 patients in 6-months = 16.4 per 100 000) 
than in 2007 (77 patients = 30.8 per 100 000) which we cannot 
explain. We think it unlikely that patients may have preferentially 
presented to A&E departments elsewhere outside our Health 
Board or were misclassified on the A&E coding system, which 
was unchanged from 2007 to 2016. We think it unlikely that pa-
tients may have preferentially seen their GPs first and then been 
referred by them to hospital Medical Assessment Units (MAU) as 
patients with acute anaphylaxis are much more likely to attend 
F I G U R E  1   Number of A&E records scrutinised, cases identified and referred before (2007) and after (2016) introducing guiding 
document and patient referral pathway
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A&E immediately than consult their GP first. The post-anaphy-
laxis management document was sent to all MAUs in Wales in late 
2015 and so was available for use at each MAU from that time. 
Furthermore, a detailed search of the SAAS database failed to 
identify any patient referred from a MAU during the audit period. 
It seems unlikely that the lower incidence reflects patients who 
have previously had anaphylaxis and are treating further episodes 
at home and not attending A&E afterwards, as it is the minority 
of patients who experience recurrent anaphylaxis.10 We think it 
unlikely that many patients presenting to A&E with anaphylaxis 
may have been misdiagnosed in 2016 compared with 2007 in view 
of the increased awareness of anaphylaxis, the publication of the 
2011 NICE guidelines and our response to these guidelines.
None of the 41 patients identified as having anaphylaxis at A&E 
were previously known to the allergy service. Eighteen (44%) were re-
ferred to the SAAS, and no statements were made in any of the A&E 
records of the 23 patients not referred indicated explicitly why they 
were not referred. Suspected precipitants in 10 patients were not 
documented, and as only 2 of these were referred and 8 not referred, 
it is possible that inability to identify a suspected precipitant may pre-
dispose to non-referral. All UK A&E departments are extremely busy 
and it seems most likely that the remaining 56% were not referred 
because of the pressure under which all A&E staff work. Although 
all A&E junior doctors receive full and appropriate instruction about 
anaphylaxis during their induction, the constantly increasing number 
of patients attending A&E, chronic understaffing, high frequency of 
junior doctor rotation through A&E (4-6 monthly), the 4-hour wait-
ing time target and IT access limitations may all contribute to some 
post-emergency management arrangements being incomplete.
Adrenaline for self-administration was prescribed by A&E staff 
at the time of discharge to 14 of the 17 patients who required this. 
Adrenaline prescription was not recorded in the remaining 3, two 
of whom had known food allergy. Adrenaline autoinjectors were in 
our view justifiably not prescribed by A&E staff to 16 patients who 
had symptoms from side effects of drugs, oral allergy syndrome or 
mild wheezing, in whom appropriate changes in drug therapy and 
food avoidance was advised. These are reassuring findings and indi-
cate appropriately discriminatory prescribing by A&E staff. Current 
resources are insufficient for A&E staff to meet all demands in all 
areas, and redistribution of existing resources within A&E depart-
ments is unlikely to improve post-anaphylaxis management. We 
think that the employment of more advanced nurse practitioners 
who could review such patients following recovery in a dedicated 
24-hour stay facility and more reliably refer them to the SAAS as per 
written protocol is the most likely way of improving the post-ana-
phylaxis management of these patients.
In view of the encouraging improvement in referral rates, we 
have not changed the post-anaphylaxis patient referral pathways 
suggested. As an initial step, we have however prepared an abbre-
viated document shown in the Table 1 that may be easier for busy 
junior doctors to use (full version used shown in Appendix S1). This 
A&E activity is an area that needs to be more actively targeted by 
clinical allergy specialists. We hope that other allergy specialists and 
A&E departments might find this to be a useful document to adapt 
and customize for their own particular situation.
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TA B L E  1   Post-anaphylaxis management
Identifying likely precipitant
Stop suspected drugs (eg ACE inhibitors, A2R antagonists, 
Amlodipine, NSAIDs, SSRIs, SNRIs, PPIs, Bisphosphonates, 
Tetracyclines, Statins, Finasteride, and Tamsulosin) even if 
tolerated for many years, start regular oral antihistamines and 
arrange GP follow-up
GP follow-up for known nut allergy, and for Oral Allergy Syndrome 
and specific food allergy if no epinephrine required
Allergy service referral if previously unknown nut allergy, idiopathic 
anaphylaxis, exercise ± wheat/other food induced anaphylaxis, 
stinging insect anaphylaxis or if epinephrine required for oral 
allergy syndrome or reaction to other specific food
Prescribe self-injectable epinephrine for anaphylaxis due to allergy 
to nuts, other food that is difficult to avoid (eg milk), insect venom, 
exercise-induced or idiopathic anaphylaxis
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